Knight Therapeutics Stock Analysis
| GUD Stock | CAD 5.97 0.07 1.19% |
200 Day MA 6.0222 | 50 Day MA 5.9462 | Beta 0.128 |
Knight Therapeutics holds a debt-to-equity ratio of 0.058. At this time, Knight Therapeutics' Short and Long Term Debt Total is very stable compared to the past year. As of the 13th of February 2026, Long Term Debt is likely to grow to about 32.6 M, while Net Debt is likely to drop (37 M). With a high degree of financial leverage come high-interest payments, which usually reduce Knight Therapeutics' Earnings Per Share (EPS).
Asset vs Debt
Equity vs Debt
Knight Therapeutics' liquidity is one of the most fundamental aspects of both its future profitability and its ability to meet different types of ongoing financial obligations. Knight Therapeutics' cash, liquid assets, total liabilities, and shareholder equity can be utilized to evaluate how much leverage the Company is using to sustain its current operations. For traders, higher-leverage indicators usually imply a higher risk to shareholders. In addition, it helps Knight Stock's retail investors understand whether an upcoming fall or rise in the market will negatively affect Knight Therapeutics' stakeholders.
For many companies, including Knight Therapeutics, marketable securities, inventories, and receivables are the most common assets that could be converted to cash. However, for Knight Therapeutics, the most critical issue when managing liquidity is ensuring that current assets are properly aligned with current liabilities. If they are not, Knight Therapeutics' management will need to obtain alternative financing to ensure there are always enough cash equivalents on the balance sheet to meet obligations.
Price Book 0.764 | Enterprise Value Ebitda 10.5587 | Price Sales 1.4207 | Shares Float 61.5 M | Wall Street Target Price 7.9333 |
Knight Therapeutics is fairly valued with Real Value of 5.96 and Hype Value of 5.97. The main objective of Knight Therapeutics stock analysis is to determine its intrinsic value, which is an estimate of what Knight Therapeutics is worth, separate from its market price. There are two main types of Knight Therapeutics' stock analysis: fundamental analysis and technical analysis. Fundamental analysis focuses on the financial and economic factors that affect Knight Therapeutics' performance, such as revenue growth, earnings, and financial stability. Technical analysis, on the other hand, focuses on the price and volume data of Knight Therapeutics' stock to identify patterns and trends that may indicate its future price movements.
The Knight Therapeutics stock is traded in Canada on Toronto Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in Canada. Knight Therapeutics is usually not traded on Civic Holiday, Labour Day, Thanksgiving Day, Christmas Day, Boxing Day, New Year 's Day, Family Day, Good Friday, Victoria Day, Canada Day. Knight Stock trading window is adjusted to America/Toronto timezone.
Knight |
Knight Stock Analysis Notes
About 46.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 0.76. Some equities with similar Price to Book (P/B) outperform the market in the long run. Knight Therapeutics has Price/Earnings (P/E) ratio of 133.9. The entity recorded a loss per share of 0.04. The firm had not issued any dividends in recent years. Knight Therapeutics Inc. operates as a specialty pharmaceutical company in Canada and internationally. The company was incorporated in 2013 and is headquartered in Montreal, Canada. KNIGHT THERAPEUTICS operates under Drug ManufacturersSpecialty Generic classification in Canada and is traded on Toronto Stock Exchange. To learn more about Knight Therapeutics call Jonathan Goodman at 514-484-4483 or check out https://www.knighttx.com.Knight Therapeutics Quarterly Total Revenue |
|
Knight Therapeutics Investment Alerts
| Knight Therapeutics generated a negative expected return over the last 90 days | |
| About 46.0% of the company shares are held by company insiders | |
| Latest headline from news.google.com: Technical Analysis and Trading Signals - Stock Traders Daily |
Knight Largest EPS Surprises
Earnings surprises can significantly impact Knight Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2023-08-10 | 2023-06-30 | 0.03 | 0.02 | -0.01 | 33 | ||
2022-08-11 | 2022-06-30 | 0.08 | 0.09 | 0.01 | 12 | ||
2021-05-14 | 2021-03-31 | 0.04 | 0.05 | 0.01 | 25 |
Knight Market Capitalization
The company currently falls under 'Small-Cap' category with a current market capitalization of 587.95 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Knight Therapeutics's market, we take the total number of its shares issued and multiply it by Knight Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.Knight Profitablity
Knight Therapeutics' profitability indicators refer to fundamental financial ratios that showcase Knight Therapeutics' ability to generate income relative to its revenue or operating costs. If, let's say, Knight Therapeutics is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Knight Therapeutics' executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Knight Therapeutics' profitability requires more research than a typical breakdown of Knight Therapeutics' financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
The company has Profit Margin (PM) of (0.01) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of 0.01 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.01. | Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | 0.01 | 0.01 | |
| Return On Capital Employed | 0.01 | 0.01 | |
| Return On Equity | 0.01 | 0.01 |
Management Efficiency
As of the 13th of February 2026, Return On Capital Employed is likely to grow to 0.01, while Return On Tangible Assets are likely to drop 0.01. At this time, Knight Therapeutics' Total Current Assets are very stable compared to the past year. As of the 13th of February 2026, Intangibles To Total Assets is likely to grow to 0.36, while Total Assets are likely to drop about 961.1 M. Knight Therapeutics' management efficiency ratios could be used to measure how well Knight Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 7.08 | 5.54 | |
| Tangible Book Value Per Share | 4.84 | 5.80 | |
| Enterprise Value Over EBITDA | 7.11 | 7.47 | |
| Price Book Value Ratio | 0.78 | 1.11 | |
| Enterprise Value Multiple | 7.11 | 7.47 | |
| Price Fair Value | 0.78 | 1.11 | |
| Enterprise Value | 458 M | 504.9 M |
Leadership effectiveness at Knight Therapeutics is a strong indicator of its financial stability. We analyze various metrics to provide insights into the stock's investment viability.
Technical Drivers
As of the 13th of February 2026, Knight Therapeutics secures the Standard Deviation of 1.05, mean deviation of 0.8128, and Risk Adjusted Performance of (0.01). Knight Therapeutics technical analysis lets you operate historical price patterns with an objective to determine a pattern that forecasts the direction of the firm's future prices.Knight Therapeutics Price Movement Analysis
Illegal number of arguments. The output start index for this execution was zero with a total number of output elements of zero. The Weighted Moving Average calculates a weight for each value in Knight Therapeutics price series with the more recent values given greater weights.
Knight Therapeutics Predictive Daily Indicators
Knight Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Knight Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Accumulation Distribution | 2257.31 | |||
| Daily Balance Of Power | 0.5 | |||
| Rate Of Daily Change | 1.01 | |||
| Day Median Price | 5.94 | |||
| Day Typical Price | 5.95 | |||
| Price Action Indicator | 0.065 | |||
| Period Momentum Indicator | 0.07 |
Knight Therapeutics Forecast Models
Knight Therapeutics' time-series forecasting models are one of many Knight Therapeutics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Knight Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.Knight Therapeutics Debt to Cash Allocation
Knight Therapeutics has accumulated 49.46 M in total debt with debt to equity ratio (D/E) of 0.06, which may suggest the company is not taking enough advantage from borrowing. Knight Therapeutics has a current ratio of 2.26, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Knight Therapeutics until it has trouble settling it off, either with new capital or with free cash flow. So, Knight Therapeutics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Knight Therapeutics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Knight to invest in growth at high rates of return. When we think about Knight Therapeutics' use of debt, we should always consider it together with cash and equity.Knight Therapeutics Total Assets Over Time
Knight Therapeutics Assets Financed by Debt
The debt-to-assets ratio shows the degree to which Knight Therapeutics uses debt to finance its assets. It includes both long-term and short-term borrowings maturing within one year. It also includes both tangible and intangible assets, such as goodwill.Knight Therapeutics Debt Ratio | 4.54 |
Knight Net Debt
About Knight Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Knight Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Knight shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Knight Therapeutics. By using and applying Knight Stock analysis, traders can create a robust methodology for identifying Knight entry and exit points for their positions.
| Last Reported | Projected for Next Year | ||
| Pretax Profit Margin | 0.01 | 0.01 | |
| Operating Profit Margin | 0.02 | 0.02 | |
| Net Profit Margin | 0.01 | 0.01 | |
| Gross Profit Margin | 0.54 | 0.64 |
Be your own money manager
As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our stock analysis tools, you can find out how much better you can do when adding Knight Therapeutics to your portfolios without increasing risk or reducing expected return.Did you try this?
Run Stock Tickers Now
Stock TickersUse high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites |
| All Next | Launch Module |
Other Information on Investing in Knight Stock
Knight Therapeutics financial ratios help investors to determine whether Knight Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Knight with respect to the benefits of owning Knight Therapeutics security.